Sign Up Today and Learn More About Carrick Therapeutics Stock
Invest in or calculate the value of your shares in Carrick Therapeutics or other pre-IPO companies through EquityZen's platform.
Carrick Therapeutics Stock (CATR)
Carrick Therapeutics is a developer of cancer therapeutics intended to transform the way cancer is treated.
About Carrick Therapeutics Stock
Founded
2015
Industries
Science and Engineering, Health Care, Biotechnology
Carrick Therapeutics Press Mentions
Stay in the know about the latest news on Carrick Therapeutics
Substituted pyrazolo[1,5-a]pyrimidine-7-amine compounds as cdk inhibitors and …
patents • May 04, 2025
Metastatic HR+ Or HER2− Breast Cancer Market 2025: Growth Forecasts & Development Of Advanced Therapeutical Strategies
einpresswire • Mar 26, 2025
Substituted pyrazolo[1,5-a]pyrimidine-7-amine compounds as cdk inhibitors and …
patents • Feb 09, 2025
8 biotech companies advancing new treatments for breast cancer in 2024
labiotech • Nov 15, 2024
Minister O’Donovan announces €5 million for breast cancer research programme
irishtechnews • Oct 31, 2024
Carrick Therapeutics Management
Leadership team at Carrick Therapeutics
CEO
Timothy Pearson
SVP of Business Development
Jenny Horsfield
Join now and verify your accreditation status to gain access to:
- Carrick Therapeutics Current Valuation
- Carrick Therapeutics Stock Price
- Carrick Therapeutics Management
- Available deals in Carrick Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Carrick Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Carrick Therapeutics Revenue and Financials
- Carrick Therapeutics Highlights
- Carrick Therapeutics Business Model
- Carrick Therapeutics Risk Factors
- Carrick Therapeutics Research Report from SACRA Research
Trading Carrick Therapeutics Stock
How to invest in Carrick Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Carrick Therapeutics through EquityZen funds. These investments are made available by existing Carrick Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Carrick Therapeutics stock?
Shareholders can sell their Carrick Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 370K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
